TNF Inhibitors: Lessons From Immunogenicity
|
|
- Earl Perry
- 6 years ago
- Views:
Transcription
1 TNF Inhibitors: Lessons From Immunogenicity Edward Keystone, MD, FRCP(C) Professor of Medicine University of Toronto Toronto, Canada Edward Keystone, MD FRCP(C) Disclosures Sources of Funding for Research: Abbott Laboratories; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Baylis Medical; Bristol-Myers Squibb; F. Hoffmann-La Roche Inc; Janssen Inc, Lilly Pharmaceuticals, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, Sanofi-Aventis, UCB. Consulting Agreements/Advisory Board Membership: Abbott Laboratories; AstraZeneca Pharma, Biotest, Bristol-Myers Squibb Company; F. Hoffmann-La Roche Inc; Genentech Inc; Jannsen Inc, Lilly Pharmaceuticals; Merck, Nycomed, Pfizer Pharmaceuticals, UCB; Speaker Honoraria Agreements: Abbott Laboratories; Astrazeneca LP; Bristol-Myers Squibb Canada; F. Hoffmann-La Roche Inc.; Janssen Inc.; Pfizer Pharmaceuticals; UCB; Amgen Financial Interests/Stock Ownership: None Discussion of Off-Label, Investigational, or Experimental Drug Use: None Revised May 2013
2 Outline Targets of Immunogenicity Factors Affecting Immunogenicity Clinical Implications Proposed Treatment Algorithm 2007
3 Etanercept (Enbrel ) Three classes of TNF antagonists: Fusion proteins, Antibodies, Pegylated Fab Fragments Receptor Infliximab (Remicade ) Fab Adalimumab (Humira ) Fab Golimumab Certolizumab pegol (Cimzia ) Fab IgG1 Fc IgG1 Fc IgG1 Fc PEG Recombinant receptor/fc fusion protein Monoclon al antibody PEGylated Fab fragment 40 kda PEG (2 20 kda) Weir N, Athwal D, et al. Therapy. 2006;3: Anti-Drug Antibodies Are Increased In All TNFis Managed Healthcare Training Audience Date Company Confidential 2013
4 Antidrug Antibodies (ADAb) to TNF-Specific Neutralising Agents In Chronic Inflammatory Diseases: A Real Issue, A Clinical Perspective Vincent FB et al. Ann Rheum Dis 2012;0:1-9 Managed Healthcare Training Audience Date Company Confidential 2013 INFLIXIMAB: Incidence, Clinical And Biological Associations Of Anti-drug Antibodies = 6-61% Vincent FB et al. Ann Rheum Dis 2012 Managed Healthcare Training Audience Date Company Confidential
5 ADALIMUMAB: Incidence, Clinical And Biological Associations Of Anti-drug Antibodies In The Literature = % Vincent FB et al. Ann Rheum Dis 2012 Managed Healthcare Training Audience Date Company Confidential 2013 ETANERCEPT: Incidence, Clinical And Biological Associations Of Anti-drug Antibodies = 0-18% Vincent FB et al. Ann Rheum Dis 2012 Managed Healthcare Training Audience Date Company Confidential 2013
6 CERTOLIZUMAB: Incidence, Clinical & Biological Associations of anti-drug Antibodies = 3-25% Vincent FB et al. Ann Rheum Dis 2012 Managed Healthcare Training Audience Date Company Confidential 2013 GOLIMUMAB: Incidence, Clinical & Biological Associations of anti-drug Antibodies = 0-7.2% Vincent FB et al. Ann Rheum Dis 2012 Managed Healthcare Training Audience Date Company Confidential 2013
7 Take Home Message Anti-Drug Abs observed with all TNFis: in RA and non-ra disorders variable between TNFis Anti-Drug Abs inversely correlated with: serum trough level clinical response MTX use Anti-Drug Abs correlated with A/Es: mainly infusion reactions Managed Healthcare Training Audience Date Company Confidential 2013 Factors Related to Immunogenicity & Its Detection Factors Contributing to Immunogenicity Dose, frequency, duration and route of administration 1 Concomitant medication 2 Genetics, immune and nutritional status of the patient 1 Antibody isotype 1 IgG1, IgG2, IgG3, IgG4 Function of the therapeutic target 1 Size and complexity of the therapeutic agent 1 Factors Contributing to the Detection of Anti-drug Antibody Clearance rate of the immunecomplex 1 Presence of soluble drug 1 Type of detection assay 1 Timing of antibody determination 1 antibody titer 2 1. Cassinotti A, et al. Inflamm Bowel Dis. 2009;15: Hermeling S, et al. Pharm Res. 2004;21:
8 Positive Interpretation of Results Positive for antibodies regardless of drug levels Negative Negative for antibodies Undetectable drug levels Inconclusive Negative for antibodies Detectable drug levels Important Limitations Regarding Immunogenicity Information Data on antibody development and immunogenicity are highly dependent on the sensitivity and specificity of the assay Interpretation requires information about drug levels at the time of sampling Very few assays in the public domain For these reasons, comparison of the incidence of antibodies between products may be misleading.
9 Practical Clinical Implications of Anti-Drug Abs Impact on safety Impact on efficacy Impact on TNFi dose escalation Impact on switching strategies Impact on Safety
10 Proportion of Infusions with Infusion Reactions Proportion of Infusions with Infusion Reactions Safety - Infusions with Infusion Reactions by Antibody-to-Infliximab (ATI) Status ATTRACT through week ACCENT I through week Positive* 37 / 329 Inconclusive* 93 / 3092 Negative* 35 / 1224 Positive* 42 / 254 Inconclusive* 47 / 1470 Negative* 55 / 656 Antibody-to-Infliximab Status Antibody-to-Infliximab Status *patients with evaluable samples 2 Lancet 2002; 359: Take Home Message Anti-drug Ab increase the risk of infusion reactions with TNFi s
11 Impact on Efficacy The Immunogenicity Of anti-tnf Therapy : A Systemic Review Of The Literature With A Meta-analysis Garces S, Demenegeot J and Benito-Garcia E. Ann Rheum Dis 2012; 0:1-9. doi: /annrheumdis
12 Effect of Anti-Drug Ab Positivity on a TNF Response Garces S et al. Ann Rheum Dis 2012; 0:1-9. doi: /annrheumdis Clinical Characteristics To Address Effect Of Anti-Drug Abs On Drug Response & The Effect Of Immunosuppression On Anti-Drug Ab Detection Garces S et al. Ann Rheum Dis 2012; 0:1-9. doi: /annrheumdis
13 Take Home Message The Effect Of Anti-drug Abs On The TNFi Response Is Influenced By. MTX Rheumatoid Arthritis vs other diseases Initiation of higher biologic dose? Antidrug Antibodies : Association With Disease Activity and Treatment Failure During Long-term Follow-up Bartelds et al, JAMA, April 2013, Vol 305, No. 4, pp
14 Effect of anti-adalimumab Abs on Overall Pt Dropout & Dropout Due to Rx Failure Bartelds, Geertje et al, JAMA, April 2013, Vol 305, No. 4, pp Effect of anti-adalimumab Abs on Sustained Disease Activity & Remission Bartelds, Geertje et al, JAMA, April 2013, Vol 305, No. 4, pp
15 Take Home Message Anti- Drug Abs increased dropout rate as a consequence of loss of efficacy. Anti- Drug Abs reduced sustainability of LDAS and remission Effect of Serum TNFi Levels on Clinical Outcomes
16 CRP < 5mg/dL (% of patients) Complete Endoscopic Remission (% of patients) Remisssion (% of patients) Endoscopic Improvement >75% (% of patients) Effect of SerumTrough Levels of Infliximab in Crohn s 52 wks MSH, Toronto Remission CRP P< P< Trough Serum Infliximab Detectable 0 P< Endoscopic improvement 47 P= Complete endoscopic remission Undetectable Maser EA et al. Clin Gastroenterol Hepatol 2006;4: Anti-adalimumab Antibodies & Serum Adalimumab Concentrations In RA Bartelds GM et al., Ann Rheum Dis 2007; 66:
17 Serum Trough Levels Of Adalimumab In Psoriasis Adalimumab Trough Concentrations per PASI Response Level P < P = P = * 4* Lecluse LLA, et al. Arch Dermatol. 2010;146(2): Serum Trough Levels of Infliximab In Ankylosing Spondylitis Serum Trough Infliximab Level for Responders and Non-Responders P=0.018 De Vries MK, et al. Ann Rheum Dis. 2007;66:
18 Levels Of Etanercept In Ankylosing Spondylitis Etanercept Levels for ASAS Responders and Non-Responders De Vries MK, et al. Ann Rheum Dis. 2009;68: Take Home Message Serum trough levels of inflixmab & adalimumab affect clinical outcomes in RA and non-ra conditions. Trough levels of etanercept do not affect clinical outcomes in AS.
19 Subjects with a response Impact of Anti-Drug Abs On TNFi Dose Escalation Clinical Outcomes in Crohn s Disease Mayo Clinic 100 Detectable ATI 100 Subtherapeutic IFX 75 p< p< n=17 n=12 n=29 n=6 0 Increase IFX Change Anti- TNF Response to test Increase IFX Change Anti- TNF Response to test Afif et al. Am J Gastroenterol. 2010; 105(5):
20 Take Home Message Dose escalation is useful in patients with a subtherapeutic dose of a TNFi Dose escalation unhelpful in patients with detectable anti-drug Abs and therapeutic trough levels BUT.. Some reports show dose escalation can boost immune response with increased infusion reactions While other reports show decrease in anti-dug Abs and improved drug response More studies warranted. Impact of Anti-Drug Abs on TNFi Switching
21 Anti-Infliximab and Anti-Adalimumab Antibodies in Relation to Response to Adalimumab in Infliximab Switchers and Anti-TNF Naïve Patients Study Design Observational cohort study of 235 patients all treated with adalimumab 22% had previously been treated with infliximab switchers 78% were anti-tnf naive Bartelds GM, et al. Ann Rheum Dis. 2010;69: Anti-ADA status, n (%) Total populati on (N=235) Δ DAS28* all 1.6 ± 1.5 Δ DAS28* anti-ada (-) Δ DAS28* anti-ada (+) Anti-TNF naïve patients (n=183) INF switcher s (n=52) INF switcher s with anti-inf (n=33) INF switcher s w/out anti-inf (n=19) 46 (20) 32 (18) 14 (27) 11 (33) 3 (16) 1.8 ± 1.4* 0.6 ± 1.3 Results Frequency of Anti-Adalimumab (a-ada) Antibodies and Clinical Response After 28 Weeks of Adalimumab Treatment 1.7 ± ± 1.4* 0.6 ± ± ± 1.3* 0.5 ± ± ± 1.1* 0.4 ± ± ± 1.4 NS 0.7 ± 1.4 Bartelds GM, et al. Ann Rheum Dis. 2010;69:
22 Results & Conclusion Increased likelihood of anti-ada Ab in patients with anti-inf Ab (rapid metabolizers with low serum drug concentrations?) ADA switchers after INF without a-inf Abs had a reduced response. ADA switchers after INF with a-inf Ab had a good response These results have implications for choice of biologic in TNFi-IRs The Presence Or Absence Of Antibodies To Infliximab Or Adalimumab Determines The Outcome Of Switching To Etanercept Jamnitski Anna et al Ann Rheum Dis 2011; 70: doi:
23 Results Improvement in DAS28 in TNF Naïve Patients vs Switchers P=0.001 P=0.743 P=0.017 Jamnitski A, et al. Ann Rheum Dis. 2011;70(2): Implications of anti-drug Abs to Biologic Switching If anti-drug Abs present to first TNFi consider a second TNFi But possible increase in anti-drug Abs to second TNFi (Bartelds et al) If no anti-drug Ab to first TNFi. consider a biologic with a different MOA (i.e. a non-tnfi)
24 Nice Thought, But There is no comparative data on the response of a second TNFi to that of a biologic with a different MOA in the presence or absence of anti-drug Abs to the first TNFi!
25 Take Home Message Serum trough levels of TNFi may be helpful in treatment decisions to dose escalate or switch TNFis Anti-drug levels may be helpful in treatment decisions to switch to another TNFi or a non- TNFi biologic. Can one construct an algorithm for monitoring serum &/or anti-drug Ab in TNFi failures? Of Course
26 Algorithm For Monitoring Serum TNFi Levels & Anti-Drug Abs & in Patients with Failure of a-tnf Therapy Vincent, Fabien et al., Ann Rheum Dis 2012; 0: 1-14.doi: /annrheumdis Although Immunogenicity May Help Explain Clinical Outcomes, Its Role In Clinical Practice Remains Unclear. More Prospective Data Is Needed!
27 Thank You! Results & Conclusions Response to etanercept did not differ between patients who were anti-tnf naïve and switchers with anti-biologic antibodies to the previous TNFi However, switchers without anti-biologic antibodies to the previous TNFi had a diminished response;? Non TNF-dependent Jamnitski A, et al. Ann Rheum Dis. 2011;70(2):
28 Effect of Serum Trough Levels of Adalimumab in Plaque Psoriasis Study Design Prospective observational study cohort of 29 patients with psoriasis starting a regimen of adalimumab 40mg every other week after an initial dose of 80 mg Patients who had inadequate response could be dosed weekly Lecluse LLA, et al. Arch Dermatol. 2010;146(2): Serum Trough Levels of Infliximab in Ankylosing Spondylitis Study Design Prospective clinical trial of 38 patients with AS treated with infliximab 5mg/kg every 6 weeks De Vries MK, et al. Ann Rheum Dis. 2007;66:
29 Effect of Serum Trough Levels of Etanercept in Ankylosing Spondylitis Study Design 53 consecutive patients with AS treated with etanercept 25 mg twice weekly Sera collected at baseline, 3 and 6 months De Vries MK, et al. Ann Rheum Dis. 2009;68: Results Percentage of Patients With and Without ATI Fulfilling ASAS-20 Response Criteria De Vries MK, et al. Ann Rheum Dis. 2007;66:
30 But. Before Routine Screening International consensus for further studies of impact of a-drug Abs and drug concentration Standardization of drug concentration detection methods Definition of cut-off values for defining presence of anti- Drug Abs Definition of therapeutic range of concentration for each TNFi
What I Have Learned Over the Years - Keystone s Top 10 -
What I Have Learned Over the Years - Keystone s Top 10 - Edward Keystone, MD FRCP(C) Professor of Medicine University of Toronto, CANADA Ontario Rheumatology Association Meeting Muskoka, Canada Sunday,
More informationAssociation Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1017-7 Program Prior Authorization/Notification Medication Cimzia (certolizumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,
More informationCorporate Medical Policy
Corporate Medical Policy Measurement of Serum Antibodies to Infliximab, Adalimumab and File Name: Origination: Last CAP Review: Next CAP Review: Last Review: measurement_of_serum_antibodies_to_infliximab_and_adalimumab
More informationImmunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationPositioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
More informationMEDICAL POLICY II. III. SUBJECT: MEASUREMENT OF SERUM ANTIBODIES TO INFLIXIMAB, ADALIMUMAB, AND VEDOLIZUMAB
MEDICAL POLICY SUBJECT: MEASUREMENT OF SERUM ANTIBODIES TO INFLIXIMAB, ADALIMUMAB, AND PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not
More informationTreatment failure with antagonists of TNF-α: mechanisms and implications for the care of patients
226 Eur. Cytokine Netw., Vol. 21 n 4, December 2010, 226-31 REVIEW ARTICLE Treatment failure with antagonists of TNF-α: mechanisms and implications for the care of patients Marine Desroches, Gauthier Louis,
More informationCADTH Therapeutic Review Panel
Therapeutic Review Panel Final Recommendations Biological Response Modifier Agents for Adults with Rheumatoid Arthritis July 2010 RECOMMENDATIONS The Therapeutic Review Panel (TRP) recommends that in adult
More informationCLINICAL BRIEFS. Tumor Necrosis Factor Inhibitors In the Treatment of Chronic Inflammatory Diseases
CLINICAL BRIEFS Tumor Necrosis Factor Inhibitors In the Treatment of Chronic Inflammatory Diseases A review of immunogenicity and potential implications By Joseph Flood, MD, FACR President, Musculoskeletal
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
DERBYSHIRE JOINT AREA PRERIBING COMMITTEE (JAPC) Derbyshire commissioning guidance on biologic drugs f the treatment of Rheumatoid arthritis with methotrexate This algithm is a tool to aid the implementation
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationAvailable Data on Pediatric Exposure Response a Clinician s Perspective
Available Data on Pediatric Exposure Response a Clinician s Perspective Marla Dubinsky, MD Professor of Pediatrics and Medicine Chief Pediatric GI and Nutrition Co-Director Susan and Leonard Feinstein
More informationDrugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending
Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationDrug Class Review Targeted Immune Modulators
Drug Class Review Targeted Immune Modulators Final Update 5 Report June 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Measurement of Serum Antibodies to Page 1 of 20 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Measurement of Serum Antibodies to Infliximab and Adalimumab Professional
More informationClinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab
Clinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab Clinical Policy Number: 01.01.03 Effective Date: January 1, 2016 Initial Review Date: September 16, 2015 Most Recent
More informationDrug Class Review Targeted Immune Modulators
Drug Class Review Targeted Immune Modulators Final Update 3 Report March 2012 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of the is to summarize
More informationMedical Policy. MP Measurement of Serum Antibodies to Infliximab and Adalimumab
Medical Policy BCBSA Ref. policy: 2.04.84 Last Review: 11/15/2018 Effective Date: 11/15/2018 Section: Medicine Related Policies 9.01.502 Experimental / Investigational Services DISCLAIMER Our medical policies
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Measurement of Serum Antibodies to Infliximab Page 1 of 8 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Measurement of Serum Antibodies to Infliximab Professional
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationOptimal Use of Immunomodulators and Biologics
3/17/214 Optimal Use of Immunomodulators and Biologics Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota, U.S.A. Loftus Disclosures
More informationHow to use infliximab?
How to use infliximab? Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Gasthuisberg Leuven The how to use infliximab rules Before starting IFX: try optimizing chances for response!
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationCertolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line
Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited
More informationTUBERCULOSIS AND THE TNF-α INHIBITORS. Lloyd Friedman, M.D. Yale University Milford Hospital
TUBERCULOSIS AND THE TNF-α INHIBITORS Lloyd Friedman, M.D. Yale University Milford Hospital Outline TNF-α Anti-TNF-α medications Rates of tuberculosis Lower rates with etanercept Screening for latent tuberculosis
More informationISSN: (Print) (Online) Journal homepage:
mabs ISSN: 1942-0862 (Print) 1942-0870 (Online) Journal homepage: https://www.tandfonline.com/loi/kmab20 Certolizumab Pegol Niti Goel & Sue Stephens To cite this article: Niti Goel & Sue Stephens (2010)
More informationCommercial Products. Medical Coverage Policy Measurement of Serum. Antibodies to Infliximab and Adalimumab
Medical Coverage Policy Measurement of Serum Antibodies to Infliximab and Adalimumab EFFECTIVE DATE: 10 02 2012 POLICY LAST UPDATED: 09 18 2018 OVERVIEW This policy documents secondary loss of response
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationDrug Level Monitoring in IBD. Objectives
Drug Level Monitoring in IBD Corey A. Siegel, MD, MS Director, Dartmouth-Hitchcock IBD Center Associate Professor of Medicine, Geisel School of Medicine at Dartmouth Objectives Review non-biologic drug
More informationchemotherapeutic agents in
Use of biologics and chemotherapeutic agents in cutaneous emergencies: Focus on lifethreatening forms of psoriasis Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan
More informationCenter for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationThe prevalence and clinical effect of immunogenicity of TNF-α blockers in patients with axial spondyloarthritis
The prevalence and clinical effect of immunogenicity of TNF-α blockers in patients with axial spondyloarthritis G. Bornstein 1,2, M. Lidar 3, P. Langevitz 3, A. Fardman 2, I. Ben-Zvi 4, C. Grossman 4 1
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationIncorporating Biologics Into Your Practice
Incorporating Biologics Into Your Practice Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Disclosure Of Relationships With Industry Amgen AbbVie Celgene
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationTherapeutic Drug Monitoring και ΙΦΝΕ το 2018
Therapeutic Drug Monitoring και ΙΦΝΕ το 2018 TDM: Ναι το χρειαζόμαστε, σε όλους και πάντοτε Κωνσταντίνος Κατσάνος Conflict of interest By means of this, the speaker confirms that he receives honoraria
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationEconomic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States
1142 Economic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States Tom Tencer, PhD 1 ; Zoe Clancy, PharmD, MS 1 ; Vidya Damera, MS 2 ; Frank Zhang MD, MPH 1 ;
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationSTUDY. Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis
STUDY Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis Lidian L. A. Lecluse, MD; Rieke J. B. Driessen, MD; Phyllis I. Spuls, MD, PhD; Elke M.
More informationHighlights of DDW 2015: Crohn s disease
Highlights of DDW 2015: Crohn s disease Mark S. Silverberg, MD, PhD, FRCPC Associate Professor of Medicine, University of Toronto Staff Gastroenterologist, Mount Sinai Hospital Senior Investigator, Lunenfeld-Tanenbaum
More informationMeasurement of Serum Antibodies to Infliximab and Adalimumab
Measurement of Serum Antibodies to Infliximab and Adalimumab Policy Number: 2.04.84 Last Review: 12/2013 Origination: 2/1/2013 Next Review: 12/2014 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationProtocol. Measurement of Serum Antibodies to Infliximab and Adalimumab
Protocol Measurement of Serum Antibodies to Infliximab and Adalimumab (20484) Medical Benefit Effective Date: 04/01/15 Next Review Date: 03/19 Preauthorization No Review Dates: 11/14, 11/15, 11/16, 03/17,
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationIl ruolo degli anticorpi anti farmaco nella pratica clinica
Il ruolo degli anticorpi anti farmaco nella pratica clinica Daniela Pugliese, MD IBD Unit Complesso Integrato Columbus Gemelli Hospital Catholic University Foundation, Rome - Italy Therapeutic Drug monitoring
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More informationETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
Program Number 2017 P 3041-8 Program Step Therapy Medications UnitedHealthcare Pharmacy Clinical Pharmacy Programs *Orencia (abatacept) *This step criteria refers to the subcutaneous formulation of abatacept
More informationRegulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.29 Subject: Humira Page: 1 of 10 Last Review Date: June 22, 2017 Humira Description Humira (adalimumab),
More information6 ADRs, 2 LOE. 2 ADRs, 4 LOE. Ineffectiveness 24 ADRs 7, 1 pt for convenience. 48% had antibodies against Infliximab at baseline
Summary of Published Switch data Table 1. Information Patients Switch from (n) Reason for switch Switch to: (n) Results Numbers Presse Med. 2002 (1) 14 Infliximab (8) (6) 6 ADRs, 2 LOE 2 ADRs, 4 LOE (8)
More informationTNF-α antagonists improve arterial stiffness in patients with rheumatoid arthritis: a meta-analysis
TNF-α antagonists improve arterial stiffness in patients with rheumatoid arthritis: a meta-analysis G.Georgiopoulos 1, D.Terentes-Printzios 1, C.Vlachopoulos 1, A.Gravos 1, P.Pietri 1, C.Georgakopoulos
More informationPsA. SIMPONI (golimumab) Rheumatoid arthritis. Psoriatic arthritis. Ankylosing spondylitis EFFICACY EFFICACY EFFICACY. QoL. QoL.
RA Rheumatoid arthritis PsA Psoriatic arthritis AS Ankylosing spondylitis EFFICACY EFFICACY EFFICACY QoL QoL QoL SAFETY SAFETY SAFETY EXPERIENCE EXPERIENCE EXPERIENCE SUMMARY SUMMARY SUMMARY Copyright
More informationBiologics and Psoriasis: The Beat Goes On
Biologics and Psoriasis: The Beat Goes On Mark Lebwohl, MD Waldman Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Mark Lebwohl is
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationMonitoring of the patients treated by Anti-TNFα : a step towards the personalized medicine.
10 th World Congress on Inflammation Paris (France) Satellite Symposium June 27 th 2011 Monitoring of the patients treated by Anti-TNFα : a step towards the personalized medicine. 1 Introduction Pr. Xavier
More informationThe future of IBD therapeutic research
The future of IBD therapeutic research Jean-Frederic Colombel, MD Director Susan and Leonard Feinstein IBD Clinical Center Icahn School of Medicine, Mount Sinai Hospital New York J-F Colombel has served
More informationJoin the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
More informationTechnology appraisal guidance Published: 26 January 2016 nice.org.uk/guidance/ta375
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed Technology
More informationTRANSPARENCY COMMITTEE OPINION. 26 April 2006
TRANSPARENCY COMMITTEE OPINION 26 April 2006 REMICADE 100 mg powder for concentrate for solution for infusion Box of 1 (CIP code: 562 070.1) Applicant : laboratoires Schering Plough List I Drug for hospital
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationTreating Rheumatologic Disease in Arizona: Good News, Bad News
Treating Rheumatologic Disease in Arizona: Good News, Bad News Jeffrey R. Lisse, M.D. Ethel P. McChesney Bilby Professor of Medicine Chief, Section of Rheumatology University of Arizona School of Medicine
More information(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationCharité - University Hospital, Free University and Humboldt University of Berlin, Berlin, Germany; 2 Sanofi Genzyme, Bridgewater, NJ, USA; 3
Efficacy and Safety of Sarilumab Versus Adalimumab in a Phase 3, Randomized, Double-blind, Monotherapy Study in Patients With Active Rheumatoid Arthritis With Intolerance or Inadequate Response to Methotrexate
More informationFor Rheumatoid Arthritis
For Rheumatoid Arthritis APRIL 2017 NOTICE: On April 14, 2017 the FDA issued a complete response letter for baricitinib indicating that the FDA is unable to approve the application in its current form
More informationof TNF inhibitors. Theo Rispens
22-09-08 Clinical implications of immunogenicity of TNF inhibitors Theo Rispens Disclosure In relation to this presentation, I declare the following, real or perceived conflicts of interest: - received
More informationPsoriatic Arthritis: New and Emergent Therapies
Psoriatic Arthritis: New and Emergent Therapies Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan Hospital New York, NY, USA DISCLOSURE OF RELEVANT RELATIONSHIPS
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationPharmacy Medical Necessity Guidelines: Orencia (abatacept)
Pharmacy Medical Necessity Guidelines: Effective: October 23, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review SQ: RXUM/ RX / Pharmacy (RX) or
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationOptimal care during pregnancy and delivery
Oxford Inflammatory Bowel Disease MasterClass Optimal care during pregnancy and delivery Professor Catherine Nelson-Piercy, London, UK Oxford Inflammatory Bowel Disease MasterClass Therapeutic goals in
More informationOptimizing the treatment of IBD through use of therapeutic drug monitoring
Optimizing the treatment of IBD through use of therapeutic drug monitoring Adam S. Cheifetz Director, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center Associate Professor of
More informationBiologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA
Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA Overview Indications and Drug Selection Contraindications
More informationScottish Medicines Consortium
Scottish Medicines Consortium etanercept 25mg vial of powder for subcutaneous injection (Enbrel ) (No. 212/05) Wyeth New indication: severe active ankylosing spondylitis inadequately controlled by conventional
More informationCost per Responder of Apremilast Versus Etanercept, Adalimumab, and Ustekinumab in Patients With Moderate to Severe Psoriasis
1108 Cost per Responder of Apremilast Versus Etanercept, Adalimumab, and Ustekinumab in Patients With Moderate to Severe Psoriasis Steven R. Feldman, MD, PhD 1 ; Tom Tencer, PhD 2 ; Zoe Clancy, PharmD,
More informationThe effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
Handling editor Tore K Kvien 1 Department of Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany 2 Department of Radiology, Charité Medical School, Berlin, Germany 3 Division of Arthritis & Rheumatic
More informationThe role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
RHEUMATOLOGY Rheumatology 2014;53:213 222 doi:10.1093/rheumatology/ket260 Advance Access publication 14 August 2013 Review The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic
More information(tofacitinib) are met.
Xeljanz (tofacitinib) Policy Number: 5.01. 560 Origination: 3/2014 Last Review: 3/2014 Next Review: 3/2015 Policy BCBSKC will provide coverage for Xeljanz (tofacitinib) when it is determined to be medically
More informationClinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
nature publishing group ORIGINAL CONTRIBUTIONS 1133 see related editorial on page 1140 Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory
More informationA Clinical Context Report
Rheumatoid Arthritis in Practice An Expert Commentary with Diane Horowitz, MD A Clinical Context Report Rheumatoid Arthritis in Practice Jointly Sponsored by: and Rheumatoid Arthritis in Practice Expert
More informationThe Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationKey findings towards optimising adalimumab treatment: the concentration-effect curve
4 Key findings towards optimising adalimumab treatment: the concentration-effect curve Mieke Pouw* Charlotte Krieckaert* Mike Nurmohamed Theo Rispens Desiree van der Kleij Lucien Aarden Gertjan Wolbink
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ruperto N, Martini A. Current and future perspectives
More information